RAPT RAPT Therapeutics, Inc. Stock Quote

RAPT [NASD]

Index	-	P/E	-	EPS (ttm)	-2.25	Insider Own	1.10%	Shs Outstand	24.45M	Perf Week	-4.86%
Market Cap	499.74M	Forward P/E	-	EPS next Y	-2.71	Insider Trans	-89.73%	Shs Float	23.71M	Perf Month	-9.20%
Income	-53.40M	PEG	-	EPS next Q	-0.59	Inst Own	87.40%	Short Float	3.63%	Perf Quarter	-37.78%
Sales	3.70M	P/S	135.06	EPS this Y	-19.00%	Inst Trans	6.85%	Short Ratio	1.94	Perf Half Y	-12.22%
Book/sh	4.50	P/B	4.56	EPS next Y	-21.00%	ROA	-42.30%	Target Price	36.17	Perf Year	-57.96%
Cash/sh	5.05	P/C	4.07	EPS next 5Y	-	ROE	-48.80%	52W Range	10.52 - 51.21	Perf YTD	4.00%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-61.45%	Beta	-
Dividend %	-	Quick Ratio	8.10	Sales past 5Y	-	Gross Margin	-	52W Low	87.66%	ATR	1.26
Employees	71	Current Ratio	8.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	41.01	Volatility	5.62% 6.29%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-36.50%	Profit Margin	-	Rel Volume	0.42	Prev Close	20.54
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	443.50K	Price	19.74
Recom	2.00	SMA20	-4.36%	SMA50	-7.77%	SMA200	-20.22%	Volume	154,147	Change	-3.89%

Jun-01-20

Initiated

H.C. Wainwright

Buy

$40

May-19-20

Initiated

Cantor Fitzgerald

Overweight

$37

Apr-13-20

Initiated

ROTH Capital

Buy

$38

Nov-25-19

Initiated

Wells Fargo

Outperform

$33

Nov-25-19

Initiated

UBS

Buy

$26

Nov-25-19

Initiated

BMO Capital Markets

Outperform

$35

Jan-07-21 04:30AM	RAPT Therapeutics' (NASDAQ:RAPT) Shareholders Are Down 28% On Their Shares Simply Wall St.
Jan-05-21 08:00AM	RAPT Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-20 10:16AM	5 Value Stocks In The Healthcare Sector Benzinga -5.98%
Dec-15-20 11:26PM	Is RAPT A Good Stock To Buy Now? Insider Monkey
Nov-23-20 08:00AM	RAPT Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire +7.28%
01:24AM	Rainbows and Unicorns: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Analysts Just Became A Lot More Optimistic Simply Wall St.
Nov-16-20 08:00AM	RAPT Therapeutics Reports Third Quarter 2020 Financial Results GlobeNewswire -46.14%
07:30AM	RAPT Therapeutics Reports Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications GlobeNewswire
Nov-15-20 07:30AM	RAPT Therapeutics to Announce Initial Data from Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications GlobeNewswire
Nov-13-20 08:00AM	RAPT Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference GlobeNewswire
Nov-11-20 09:43AM	What Type Of Shareholders Make Up RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Share Registry? Simply Wall St.
Oct-14-20 08:00AM	RAPT Therapeutics Appoints Lisa Butterfield, Ph.D., and Lawrence Fong, M.D., to Scientific Advisory Board GlobeNewswire
Sep-27-20 10:25AM	The CEO, President & Director of RAPT Therapeutics, Inc. (NASDAQ:RAPT), Brian Wong, Just Bought A Few More Shares Simply Wall St.
Sep-03-20 08:32AM	RAPT Therapeutics (RAPT) Catches Eye: Stock Jumps 6.1% Zacks
08:00AM	RAPT Therapeutics to Present at Upcoming Virtual Investor Conferences GlobeNewswire
Sep-01-20 02:53PM	We're Not Worried About RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Simply Wall St. +9.66%
Aug-13-20 10:47AM	RAPT Therapeutics Reports Second Quarter 2020 Financial Results GlobeNewswire
Aug-05-20 08:00AM	RAPT Therapeutics Appoints Phyllis Loud Gray as Vice President of Human Resources GlobeNewswire
Jul-23-20 08:14PM	Wells Fargo: These 3 Strong Buy Stocks Are Must-Watch Names TipRanks
Jul-02-20 11:24AM	Insider Buying: Wendye Robbins Just Spent US$68k On RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Simply Wall St.
Jun-18-20 04:05PM	Peter Svennilson Elected to RAPT Therapeutics Board of Directors GlobeNewswire +11.34%
Jun-17-20 08:00AM	RAPT Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference GlobeNewswire +15.62%
Jun-04-20 07:49AM	RAPT Therapeutics, Inc. (NASDAQ:RAPT) Analysts Just Trimmed Their Revenue Forecasts By 12% Simply Wall St.
May-29-20 08:00AM	RAPT Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Virtual Scientific Program GlobeNewswire
May-26-20 08:00AM	RAPT Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference GlobeNewswire
May-19-20 07:47AM	Revenue Downgrade: Here's What Analysts Forecast For RAPT Therapeutics, Inc. (NASDAQ:RAPT) Simply Wall St. +6.36%
May-18-20 07:55AM	RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St.
May-17-20 10:38AM	Read This Before Selling RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Simply Wall St.
May-15-20 08:00AM	RAPT Therapeutics Highlights Early Results for RPT193 at Society for Investigative Dermatology Meeting GlobeNewswire +6.57%
May-14-20 08:00AM	RAPT Therapeutics Reports First Quarter 2020 Financial Results GlobeNewswire
08:00AM	RAPT Therapeutics Reports First Quarter 2020 Financial Results Globenewswire Test
May-12-20 08:00AM	RAPT Therapeutics to Present at the UBS Virtual Global Healthcare Conference GlobeNewswire
Mar-30-20 08:00AM	RAPT Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Mar-04-20 08:00AM	RAPT Therapeutics Announces Management Promotions GlobeNewswire +18.78%
Feb-19-20 08:00AM	RAPT Therapeutics Announces Upcoming Investor Conference Presentations GlobeNewswire
Feb-07-20 06:45AM	RAPT Therapeutics Announces Pricing of $75 Million Public Offering GlobeNewswire -10.71%
Feb-04-20 05:43PM	RAPT Therapeutics Announces Proposed Offering of Common Stock GlobeNewswire
Jan-31-20 11:27AM	We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth Simply Wall St.
Jan-07-20 08:00AM	RAPT Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-16-19 08:00AM	RAPT Therapeutics to be Added to the Russell 2000® and Russell Microcap® Indices GlobeNewswire
Dec-11-19 08:00AM	RAPT Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights GlobeNewswire -7.44%
Dec-10-19 08:00AM	RAPT Therapeutics Appoints Mary Ann Gray, Ph.D., to Board of Directors GlobeNewswire
Dec-04-19 08:00AM	RAPT Therapeutics Appoints Rodney Young as Chief Financial Officer GlobeNewswire +10.34%
07:06AM	The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug Benzinga
Dec-03-19 04:05PM	RAPT Therapeutics and Hanmi Pharmaceutical Announce Collaboration to Develop and Commercialize FLX475 in Asia GlobeNewswire +14.82%
03:29PM	Biotech IPO Frenzy Brings in 3 Stocks to Buy TipRanks
Nov-11-19 10:56AM	Weekly CEO Buys Highlight GuruFocus.com -30.25%
Oct-30-19 08:49PM	RAPT Therapeutics Announces Pricing of Initial Public Offering Business Wire
Jul-30-19 03:25PM	Rapt Therapeutics IPO: What You Need To Know Benzinga
Jul-28-19 02:08PM	IPO Outlook For The Week: Cannabis, Cancer Therapy, Sushi And Holographic AR Benzinga
Jul-05-19 05:24PM	Rapt Therapeutics files for initial public offering MarketWatch

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HO WILLIAM	Chief Medical Officer	Jan 15	Sale	21.05	1,000	21,050	67,414	Jan 15 08:52 PM
Brockstedt Dirk G.	Chief Scientific Officer	Jan 06	Sale	19.68	1,179	23,203	17,556	Jan 06 08:48 PM
Brockstedt Dirk G.	Chief Scientific Officer	Jan 05	Sale	19.76	821	16,225	18,735	Jan 06 08:48 PM
HO WILLIAM	Chief Medical Officer	Jan 04	Sale	19.75	1,000	19,750	68,414	Jan 04 08:04 PM
Brockstedt Dirk G.	Chief Scientific Officer	Dec 30	Option Exercise	6.18	9,300	57,474	19,556	Dec 31 06:09 PM
HO WILLIAM	Chief Medical Officer	Dec 15	Sale	24.55	1,000	24,550	69,414	Dec 15 09:01 PM
HO WILLIAM	Chief Medical Officer	Dec 01	Sale	21.83	1,000	21,830	70,414	Dec 01 08:37 PM
RIEFLIN WILLIAM JL	Director	Nov 19	Buy	16.22	10,000	162,200	18,000	Nov 20 03:56 PM
Robbins Wendye	Director	Nov 19	Buy	16.09	500	8,045	500	Nov 23 02:01 PM
Robbins Wendye	Director	Nov 19	Buy	16.08	500	8,040	5,100	Nov 23 02:01 PM
Brockstedt Dirk G.	Chief Scientific Officer	Nov 16	Option Exercise	6.26	9,877	61,821	20,133	Nov 18 02:15 PM
HO WILLIAM	Chief Medical Officer	Nov 16	Option Exercise	6.25	8,356	52,240	72,414	Nov 18 02:16 PM
HO WILLIAM	Chief Medical Officer	Nov 16	Sale	20.25	1,000	20,250	71,414	Nov 18 02:16 PM
Brockstedt Dirk G.	Chief Scientific Officer	Nov 16	Sale	17.01	9,877	168,008	10,256	Nov 18 02:15 PM
Brockstedt Dirk G.	Chief Scientific Officer	Nov 02	Sale	28.06	1,910	53,595	10,256	Nov 03 08:32 PM
Lam Karen C	VP, Finance and Controller	Nov 02	Sale	28.14	2,022	56,899	12,735	Nov 03 08:29 PM
HO WILLIAM	Chief Medical Officer	Nov 02	Sale	28.06	1,000	28,060	64,058	Nov 03 08:26 PM
HO WILLIAM	Chief Medical Officer	Oct 15	Sale	35.76	1,000	35,760	65,058	Oct 16 12:30 PM
Wong Brian Russell	President and CEO	Oct 12	Sale	40.05	20,000	801,040	337,000	Oct 13 07:43 PM
HO WILLIAM	Chief Medical Officer	Oct 12	Sale	40.20	2,000	80,400	66,058	Oct 13 07:40 PM
HO WILLIAM	Chief Medical Officer	Oct 01	Sale	31.18	1,000	31,180	68,058	Oct 02 02:37 PM
Robbins Wendye	Director	Sep 28	Buy	28.70	500	14,350	6,550	Sep 29 08:58 PM
HO WILLIAM	Chief Medical Officer	Sep 24	Option Exercise	6.18	2,200	13,596	69,058	Sep 25 04:44 PM
Robbins Wendye	Director	Sep 24	Buy	28.00	200	5,600	6,050	Sep 24 06:02 PM
Wong Brian Russell	President and CEO	Sep 23	Buy	30.06	2,000	60,120	357,000	Sep 23 03:11 PM
Robbins Wendye	Director	Sep 23	Buy	29.20	400	11,680	5,850	Sep 24 06:02 PM
COLUMN GROUP II, LP	10% Owner	Sep 22	Sale	30.85	608,000	18,756,800	3,835,679	Sep 23 04:52 PM
Svennilson Peter	Director	Sep 22	Sale	30.85	608,000	18,756,800	3,835,679	Sep 22 07:51 PM
HO WILLIAM	Chief Medical Officer	Sep 15	Sale	36.14	1,000	36,140	66,858	Sep 15 07:22 PM
HO WILLIAM	Chief Medical Officer	Sep 01	Sale	26.24	1,000	26,240	67,858	Sep 02 07:53 PM
Brockstedt Dirk G.	Chief Scientific Officer	Aug 17	Option Exercise	6.18	9,877	61,040	20,133	Aug 18 07:44 PM
HO WILLIAM	Chief Medical Officer	Aug 17	Sale	24.76	1,000	24,760	68,858	Aug 18 07:46 PM
Brockstedt Dirk G.	Chief Scientific Officer	Aug 17	Sale	23.93	9,877	236,328	10,256	Aug 18 07:44 PM
Svennilson Peter	Director	Aug 17	Sale	22.75	538,654	12,254,379	4,443,679	Aug 19 05:41 PM
COLUMN GROUP II, LP	10% Owner	Aug 17	Sale	22.75	538,654	12,254,379	4,443,679	Aug 19 05:39 PM
HO WILLIAM	Chief Medical Officer	Aug 03	Sale	21.54	1,000	21,540	69,858	Aug 03 07:42 PM
Robbins Wendye	Director	Jul 24	Buy	22.47	900	20,225	5,450	Jul 27 06:38 PM
HO WILLIAM	Chief Medical Officer	Jul 15	Sale	28.76	1,000	28,760	70,858	Jul 16 08:13 PM
Robbins Wendye	Director	Jul 01	Buy	26.40	1,000	26,400	4,550	Jul 01 06:16 PM
HO WILLIAM	Chief Medical Officer	Jul 01	Sale	28.61	1,000	28,610	71,858	Jul 01 07:20 PM
Robbins Wendye	Director	Jun 29	Buy	25.77	1,600	41,232	3,550	Jul 01 06:16 PM
Giordano Michael F	Director	Jun 25	Option Exercise	8.92	19,013	169,554	10,069	Jun 26 05:49 PM
Lam Karen C	VP, Finance & Controller	Jun 25	Sale	35.00	875	30,625	12,735	Jun 26 05:46 PM
Giordano Michael F	Director	Jun 25	Sale	33.37	19,013	634,464	0	Jun 26 05:49 PM
HO WILLIAM	Chief Medical Officer	Jun 15	Sale	20.95	1,000	20,950	72,858	Jun 18 06:41 PM
HO WILLIAM	Chief Medical Officer	Jun 01	Sale	18.50	1,000	18,500	73,858	Jun 02 05:49 PM
HO WILLIAM	Chief Medical Officer	May 22	Sale	18.02	7,500	135,150	74,858	May 22 08:14 PM
Brockstedt Dirk G.	Chief Scientific Officer	May 15	Option Exercise	6.18	9,877	61,040	20,133	May 18 05:11 PM
Brockstedt Dirk G.	Chief Scientific Officer	May 15	Sale	15.00	9,877	148,155	10,256	May 18 05:11 PM
Lam Karen C	VP, Finance & Controller	May 12	Option Exercise	1.86	2,777	5,165	13,610	May 13 05:15 PM
Lam Karen C	VP, Finance & Controller	May 07	Sale	15.40	1,831	28,197	10,833	May 08 05:34 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience